LeRoyLeNarzMD

Journal Articles

• Impact of Access Site on Bleeding and Ischemic Events in patients with Non-ST Segment Elevation Myocardial Infarction Treated with Prasugrel: The ACCOAST Access Substudy  
  by Porto, Bolognese, Dudek, Goldstein, Hamm, Tanquay, ten Berg, Widinsky, LeGall, Zagar, LeNarz, Miller, and Montalescot; ACCOAST investigators, JACC Cardiovascular Intervention, 1/1/2016
• Predictors of bleeding in patients with Acute Coronary Syndromes treated with Prasugel  
  Widinsky, Motovska, Bolognese, Dudek, Hamm, tenBerg, Brown, LeNarz, Miller, Montalescot; ACCOAST Investigators, Heart, 1/1/2015
• Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: Fr...  
  Dudek D, Dziewierz A, Widimsky P, Bolognese L, Goldstein P, Hamm C, Tanguay JF, LeNarz L, Miller DL, Brown E, Ten Berg J, Montalescot G; ACCOAST Investigators, Am Heart J, 1/1/2015
• Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI The ACCOAST -PCI Study  
  Gilles Montalescot, MD PhD, Collet, Ecollan, Bolognese, tenBerg, Dudek, Hamm, Widinsdy, Tanquay, Goldstein, Brown, Miller, LeNarz, Vicaut, ACCOAST Investigators, J Am Coll Cardiol, 1/23/2014
• Factors Associated with Statin Selection among Privately Insured Commercial and Medicare Patients  
  Zhao, Bae, Zhu, Kryzhanovski, LeNarz, Current Medical Research and Opinion, 1/1/2013
• Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis  
  Goodnough LT, Smith PK, Levy JH, Poston RS, Short MA, Weerakkody GJ, LeNarz LA, J Thorac Cardiovasc Surg, 1/1/2013
• Mortality Benefit with Prasugrel in TRITON - TIMI 38 Coronary Artery Bypass Grafting (CABG) Cohort: Risk Adjusted Retrospective Data Analysis  
  Peter K Smith, George J Despotis, Lawrence T Goodnough, Jerrold H Levy, Robert S. Poston, Mary A Short, Govinda J Weerakkody, LeRoy A LeNarz, J AM Coll Cardiol, 1/1/2012
• Mortality Benefit With Prasugrel in the TRITON-TIMI 38 Coronary Artery Bypass Grafting Cohort--Risk-Adjusted Retrospective Data Analysis  
  Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ, Lenarz LA, J Am Coll Cardiol, 1/1/2012
• Resource utilization and healthcare costs for acute coronary syndrome patients with and without diabetes mellitus  
  Zhao Z, Zhu B, Anderson J, Fu H, LeNarz L, J Med Econ, 1/1/2010
• Clinical end points in coronary stent trials: a case for standardized definitions  
  Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic R..., Circulation, 1/1/2007
• Comparison of Zotarolimus-eluting and sirolimus -eluting stents with native coronary disease: a randomized trial  
  Kandzari DE, Leon MB,Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M,Applegate RJ,Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ..., J AM Coll Cardiol, 1/1/2006
• Group Recommendations  
  Levy JH,Smith PK, LeNarz LA, Lemmer JH, Steinhubl SR, Despotis GJ, Goodnough LT, Ann Thorac Surg, 1/1/2000
• Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials Improve Long-term Outcome with abciximab GP IIb/IIIa blockade Evaluation of...  
  Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, Sapp SK, Cabot CF, Tcheng JE, Califf RM, Effron MB, Topol EJ, Ann Thorac Surg, 1/1/2000
• Coronary artery bypass graft in abciximab-treated patients  
  LeNarz LA., Ann Thorac Surg, 1/1/2000
• Management of esophageal gunshot wounds  
  ass LJ, LeNarz LA, Schreiber JT, Estrera AS, Ann Thorac Surg, 1/1/1987
• Improved graft patency associated with altered platelet function, induced by marine fatty acids in dogs  
  Casali R, Hale,J, LeNarz L, J Surg Res, 1/1/1986
• The Sore Psoas: A difficult diagnosis in childhood  
  Smith S, LeNarz L, Mollitt DL, and Golladay ES, J Pediatric Surgery, 1/1/1982
• Join now to see all

Abstracts/Posters

• Real World Practice Patterns of Acute Coronary Syndrome (ACS) Patients With and Without Diabetes Mellitus (DM)
  LeNarz LA et al, ISPOR, 1/26/2009
• Health Care Costs and Resource Utilization for Acute Coronary Syndrome in Patients with and Without Diabetes Mellitus
  LeNarz LA et al, ISPOR, 1/26/2009
• Medication Adherence and Persistence of Clopidogrel in Acute Coronary Syndrome Patients with and without Diabetes Mellitus
  LeNarz LA et al, ISPOR, 1/26/2009
• Clopidogrel Adherence and Persistence in a Cohort of Acute Coronary Syndrome Medicare Patients with and Without Diabetes Mellitus
  LeNarz LA et al, AMCP, 1/1/2009
• Is bleeding risk increased in patients undergoing urgent coronary bypass surgery following abciximab?
  Booth JE, Patel VB, Balog C, Miller DP, Juran NB, LeNarz L, Lincoff AM, Circulation, 1/1/1998
• Join now to see all

Lectures

• Drug Device Development-the Role of the Physician 
  1/13/2016
• Delivered 10 minute industry view on how to improve recruitment and retain patients in clinical studies. 
  Tysons Corner, Tysons, VA - 1/5/2011
• Endpoints and Duration of Followup for New DES Evaluation: What is the Optimal? 
  Washington, DC - 1/11/2008
• Real World Practice: How to expand the DES indications? 
  Washington, DC - 1/11/2008
• Real World Practice: How to expand the DES indications 
  Washington, DC - 1/11/2008
• Recap of the Last Circulatory Advisory Panel on Xience and Endeavor: Lessons to be learned 
  Washington, DC - 1/11/2008
• Emerging devices and Innovative Therapies 
  Washington, DC - 1/11/2008
• Industry challenges to bring New Products to Market 
  Washington, DC - 1/11/2008
• The ENDEAVOR Program update 
  Washington, DC - 1/11/2008
• ENDEAVOR Safety Update 
  Washington, DC - 1/11/2008
• "Iterative development of Endeavor Stents" with emphasis on the Endeavor to Resolute pK data, Regulatory interactions and lessons learned. 
  1/8/2008
• Contemporary Clinical Trial Design (consistent with the new FDA DES Guidance document). 
  1/8/2008
• DES and Safety (with emphasis of how industry is responding to the challenge of stent thrombosis ) 
  Tremblant, Canada - 1/1/2008
• Presentation on the latest Endeavor data, trial rationale, statistical assumptions and background, and dual antiplatelet issues 
  Sydney, Australia - 1/23/2007
• Preclinical and safety data for the drug Zotarolimus 
  1/10/2007
• Insights-Endeavor Resolute Clinical Program 
  Vienna, Austria - 1/7/2007
• Zotarolimus review 
  Vienna, Austria - 1/7/2007
• DES utilization in 2102 
  1/2/2007
• EuroPCR PROTECT start up meeting with announcement of the study, and the background of the study discussion/presentation. 
  1/1/2007
• Presented the drug data on Zotarolimus 
  Paris, France - 1/1/2003
• Update on Epilog, and Epistent with emphasis on the surgical bleeding data 
  Charleston, WV - 1/1/2000
• Reo PRO Retrospective analysis of surgical patient and outcomes in Epilog, Epilog Stent studies 
  Orlando, FL - 1/2/1999
• II b/IIIa use and cardiac surgery 
  Cancun, Mexico - 1/1/1999
• Emergency Cardiac Surgery following Administration of ReoPro 
  1/26/1998
• Issues of administration of ReoPro and appropriate platelet usage around the time of cardiac surgery 
  Joplin, MO - 1/23/1998
• Join now to see all